
Julia Rhodes1*, Surang Dejsirilert2, Susan A. Maloney1, Possawat Jorakate1, Anek Kaewpan1, Prasert Salika1, Thantapat Akarachotpong1, Prabda Prapasi1, Sathapana Naorat1, Peera Areerat4, Asadang Ruayajin3, Pathom Sawanpanyalert2, Pasakorn Akarasewi5, Leonard F. Peruski Jr.1, Henry C. Baggett1


Abstract

Background: Streptococcus pneumoniae is an important cause of morbidity and mortality in Southeast Asia, but regional data is limited. Updated burden estimates are critical as pneumococcal conjugate vaccine (PCV) is highly effective, but not yet included in the Expanded Program on Immunization of Thailand or neighboring countries.

Methods: We implemented automated blood culture systems in two rural Thailand provinces as part of population-based surveillance for bacteremia. Blood cultures were collected from hospitalized patients as clinically indicated.

Results: From May 2005–March 2010, 196 cases of pneumococcal bacteremia were confirmed in hospitalized patients. Of these, 57% had clinical pneumonia, 20% required mechanical ventilation, and 23% (n = 46) died. Antibiotic use before blood culture was confirmed in 25% of those with blood culture. Annual incidence of hospitalized pneumococcal bacteremia was 3.6 per 100,000 person-years; rates were higher among children aged <5 years at 11.7 and adults ≥65 years at 14.2, and highest among infants <1 year at 33.8. The median monthly case count was higher during December–March compared to the rest of the year 6.0 vs. 1.0 (p<0.001). The most common serotypes were 23F (16%) and 14 (14%); 61% (74% in patients <5 years) were serotypes in the 10-valent PCV (PCV 10) and 82% (92% in <5 years) in PCV 13. All isolates were sensitive to penicillin, but non-susceptibility was high for co-trimoxazole (57%), erythromycin (30%), and clindamycin (20%).

Conclusions: We demonstrated a high pneumococcal bacteremia burden, yet underestimated incidence because we captured only hospitalized cases, and because pre-culture antibiotics were frequently used. Our findings together with prior research indicate that PCV would likely have high serotype coverage in Thailand. These findings will complement ongoing cost-effectiveness analyses and support vaccine policy evaluation in Thailand and the region.

Introduction

In 2009, The Hib and Pneumococcal Global Burden of Disease Study Team estimated that Streptococcus pneumoniae caused nearly 5.5 million meningitis, sepsis, and pneumonia cases and >185,000 deaths in Southeast Asia annually, but noted that regional prevention decisions, ‘will need to be made on the basis of limited regional data’ [1]. Similarly, The Asian Strategic Alliance for Pneumococcal Disease Prevention concluded that ‘pneumococcal disease is an important cause of morbidity and mortality in the Asian region’ and highlighted the ‘urgent’ need for ‘more substantial studies’ describing invasive pneumococcal disease burden in the Asia region [2].

Although WHO recommends pneumococcal conjugate vaccine (PCV) vaccination even in the absence of local data, policymakers often require local data to weigh costs and benefits [3]. Besides a paucity of local data, policymakers in Southeast Asian countries are faced with weighing the potential benefits of PCV against those...
of several other effective vaccines, including those against rotavirus, influenza, and human papillomavirus. Currently, PCV is not included in the National Expanded Programs of Immunization of Thailand or neighboring countries, though PCV it is available on the private market in Thailand [4].

Cost reductions are anticipated as the PCV Advanced Market Commitment is expected to increase demand, mass production, and manufacturer competition [5]. We aim to provide local and regional data to inform decision making as these changes occur. Previously, we published the first population-based estimates of pneumococcal bacteremia incidence in Southeast Asia [6]. The purpose of this report is to update these estimates and to contribute to an evidence base upon which sound policy decisions can be made.

Methods

Setting

The Thailand International Emerging Infections Program (IEIP) is part of a collaboration between the Thailand Ministry of Public Health and the U.S. Centers for Disease Control and Prevention. We conduct surveillance for community-acquired pneumonia requiring hospitalization in Sa Kaeo and Nakhon Phanom provinces, where the combined populations total 1.2 million, including >80,000 children <5 years [7]. Pneumonia surveillance is conducted at all 18 district and military hospitals and both provincial hospitals. Bloodstream infection surveillance began in all hospitals in May 2005 in Sa Kaeo and in November 2005 in Nakhon Phanom with the implementation of automated blood culture systems. Published detailed descriptions of these surveillance systems are available, [6,8].

Patients

Physicians request blood cultures from hospitalized patients as clinically indicated. Limited data (age, province, and pre-blood culture antibiotic use) are available for patients who are in the bloodstream infection surveillance system only. Detailed clinical and demographic information is available for patients who were also captured in the IEIP pneumonia surveillance system.

Specimen Collection and Laboratory Methods

Blood cultures collected at district hospitals were transported at 15–30°C within 24 hours and processed at provincial hospital laboratories using the BactT/ALERT® 3D microbial detection system (bioMerieux). Each blood specimen was divided between a bottle optimized for standard aerobic growth and a bottle for 3D microbial detection (H3D microbial detection system). Blood cultures performed in these 2 provinces were positive for any pathogen, S. pneumoniae was isolated from the blood of 196 patients: 92 from Sa Kaeo province and 104 from Nakhon Phanom. S. pneumoniae was isolated from 0.33% of 27,655 blood cultures in Sa Kaeo compared to 0.26% (104/39,855) in Nakhon Phanom.

Among all patients with blood cultures, 25% were less than 5 years old and 25% were 65 years and older (Table 1). Deaths were more common among patients with pneumococcal bacteremia from Sa Kaeo: 37% (n = 34) in SK vs. 12% (n = 12) in NP. Additional clinical details were available for 130 of 196 patients with pneumococcal bacteremia who were also captured by IEIP's pneumonia surveillance system. Of these, 86% had respiratory symptoms, 100% had evidence of acute infection and 86% (111/ 130) had both, and thus met IEIP's criteria for clinical pneumonia. Pneumonia (ICD-10 codes J14–J19) was the discharge diagnosis for 45% (58/130) and septicemia (ICD-10 code A41.9) for another 22% (29/130). Case-patients from Sa Kaeo were more likely to receive oxygen or be intubated: oxygen use (77% in SK vs. 50% in NP, p < 0.001), intubation (46% in SK vs. 16% in NP, p<0.001), which is consistent with the higher case fatality rate observed in Sa Kaeo.

Antibiotic use before blood culture was common; 25.4% (11,123/43,720) of those tested had serum antimicrobial activity. Among pneumococcal bacteremia cases, serum antimicrobial activity was found in only 5 of the 135 tested (3.7%).

Hospitalized pneumococcal bacteremia incidence rates were highest among young children and older adults and varied by year (Figure 1). Overall incidence ranged from 2.3 per 100,000 person-years in 2006 to 4.1 in 2009 (data for 2005 and 2010 were incomplete and not considered). Among children less than 5 years old, the highest annual incidence rate was observed in 2007: 18.5 per 100,000. Among infants <1 year old, the average annual incidence was 33.8 per 100,000 (95% CI 21.4, 50.7).

The median number of pneumococcal bacteremia cases per month was significantly higher during December through March compared to the rest of the year: 6.0 cases per month during December-March vs. 1.0 during April-November (p<0.001) (Figure 2). This difference was observed in both Sa Kaeo and Nakhon Phanom provinces (data not shown).

Serotyping was completed for 191 (97%) of 196 isolates and 39 (98%) of 40 isolates from children <5 years old. Serotypes 14 and 23F were most common among both children and adults; by contrast, serotype 3 was common among adults, but not found in children <5 years old.
Among children aged <5 years, serotypes contained in the current 10- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) comprised 74%, and 92% of cases, respectively, exceeding the proportions among cases overall (Figure 3).

Antibiotic susceptibility testing was available for 193/196 isolates with the results as follows: co-trimoxazole non-susceptible.

Table 1. Clinical characteristics of patients with blood culture and hospitalized pneumococcal bacteremia cases in rural Thailand, May 2005–March 2010.

<table>
<thead>
<tr>
<th>Age</th>
<th>All patients with blood culture N = 67,516</th>
<th>All pneumococcal bacteremia cases N = 196</th>
<th>Pneumococcal bacteremia cases captured in pneumonia surveillance N = 130</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>&lt;5</td>
<td>16,908</td>
<td>25.0</td>
<td>40</td>
</tr>
<tr>
<td>5–19</td>
<td>6,532</td>
<td>9.7</td>
<td>20</td>
</tr>
<tr>
<td>20–49</td>
<td>14,700</td>
<td>21.8</td>
<td>50</td>
</tr>
<tr>
<td>50–64</td>
<td>12,341</td>
<td>18.3</td>
<td>36</td>
</tr>
<tr>
<td>65+</td>
<td>17,029</td>
<td>25.2</td>
<td>50</td>
</tr>
</tbody>
</table>

Any respiratory symptoms

- Cough
- Dyspnea
- Tachynea

Evidence of acute infection

- Documented Fever
- Fever History
- Elevated White Blood Cell Count

Evidence of complicated illness

- Oxygen
- Intubation

Outcome

- Discharge
- Transfer
- Death
- Self-discharge
- Missing

doi:10.1371/journal.pone.0066038.t001

Figure 1. Hospitalized pneumococcal bacteremia incidence rates by year and age in rural Thailand, May 2005 to March 2010. Overall incidence 3.5 per 100,000 person-years, 95% CI (3.1, 4.1).

doi:10.1371/journal.pone.0066038.g001
ity was 57% (n = 109); erythromycin 30% (n = 57); clindamycin 21% (n = 40); chloramphenicol 12% (n = 23). All isolates were susceptible to penicillin and cefotaxime. Non-susceptibility to 3 or more of the above antibiotics was observed in 18% (35/193). Isolates with serotypes included in PCV10 were more likely to be non-susceptible to co-trimoxazole, erythromycin, and clindamycin compared to non-PCV10 serotype isolates: 63% vs. 45% for co-trimoxazole; 42% vs. 10% for erythromycin; and 30% vs. 5.5% for clindamycin.

Discussion

Based on 196 S. pneumoniae isolates collected during 4.4 years of bloodstream infection surveillance in 2 rural provinces, we estimated the overall incidence of hospitalization for pneumococcal bacteremia in rural Thailand at 3.5 per 100,000 person-years. Rates were highest among children <5 years old (11.1 per 100,000 person-years) and adults 65 years and older (13.6 per 100,000 person-years).

These findings demonstrate that S. pneumoniae is an important cause of severe disease requiring hospitalization in Thailand. However, these data certainly underestimate the true incidence of pneumococcal bacteremia. First, we only captured hospitalized cases, and data from the United States suggest that most pneumococcal bacteremia cases in young children occur among outpatients [14]. Second, despite increased use of blood cultures since implementation of automated blood culture processing in 2005, many patients who would likely have blood culture performed in higher resource settings do not receive them in rural Thailand. From May 2005 through June 2007, only 66% of patients with indications for blood culture had a culture performed and for patients <5 years old the proportion was just 47% [6]. Furthermore, pre-culture antibiotic use remains common in this setting. We recently examined this issue and estimated that pre-culture antibiotics reduced our pneumococcal bacteremia inci-
idence rates by 32% overall and 39% in children <5 years of age [12]. Finally, our surveillance does not include other manifestations of invasive pneumococcal disease, such as meningitis, arthritis or osteomyelitis. These incidence estimates are comparable to our previously reported estimates examining 72 S. pneumoniae isolates from 23,053 blood cultures performed from May 2005 through June 2007 [6]. However, our previous report included estimates based on a combination of cases identified via S. pneumoniae isolation and cases identified only by Binax NOW® immunochromatographic test (ICT) on broth of blood cultures that had a positive signal in the Bact/ALERT® machine but were negative on sub-culture (alarm positive, sub-culture negative). The current report does not include these ICT-only cases, because more recent investigations indicate false-positive tests can occur [15] and we are formally evaluating this unlicensed application of ICT. Alarm positive, sub-culture negative bottles continue to pose a dilemma in our laboratories; from January through March 2010, 89 (2.2%) of 3891 blood cultures were alarm positive, sub-culture negative.

The proportion of fatal cases in Nakhon Phanom province (12%) was comparable to that reported in other publications from Thailand: 9.2% from Sirirongpreeda et al. [16] (all invasive pneumococcal disease), 16% from Netsawang et al. [19] (non-meningitis), 13.3% (non-meningitis) in Suwanpakdee et al. [17]. By comparison, the case fatality rate in Sa Kao province (37%) seemed unusually high. Unfortunately, data detailing clinical characteristics, treatment, and underlying conditions were not available to investigate this unusually high case fatality rate. However, our data do suggest that severity of illness differed between the 2 provinces, with substantially more patients in Sa Kao requiring oxygen and intubation.

We documented consistent, statistically significant seasonal increases in pneumococcal bacteremia from December through March, which substantiates the seasonal increase noted in other reports from Thailand [16], [17], [19], [20]. This seasonal pattern coincides, approximately, with Thailand’s cool season (November through February) and the seasonal increases in pneumococcal disease observed in the U.S. and other temperate regions during the winter months [21,22]. Interestingly, the pneumococcal bacteremia peaks in Thailand occurred during opposite times of year as Thailand’s usual influenza season [23,24], which differs from temperate climates where invasive pneumococcal disease and influenza peaks coincide [25]. This report includes data during the 2009 influenza pandemic, which first peaked in Thailand from July to September 2009, during which time pneumococcal bacteremia rates were low (Figure 2). We observed that a high proportion of pneumococcal bacteremia cases among children aged <5 years were caused by serotypes covered by PCV10, and that with the addition of PCV13 serotypes, coverage increases from 74% to 92% for children <5 years old and from 61% to 82% overall. In a 2010 report, Thai researchers in the Bangkok area found that a similarly high proportion of IPD cases among children aged <5 years were caused by vaccine serotypes: 70% and 81% for PCV7 and 13 respectively [26]. The Thailand National Institute of Health reported even higher proportions of vaccine serotypes among children aged <5 years with invasive disease (80% for PCV10 and 92% for PCV13) [27]. Taken together these findings provide strong evidence that high coverage could be expected from PCV13 in Thailand.

All pneumococcal isolates were sensitive to penicillin, although we observed high rates of antibiotic non-susceptibility to a variety of other drugs, which is in agreement with many reports from Thailand [16,18,19,20] and the region [29]. Our finding that antibiotic non-susceptibility is significantly higher among PCV serotypes corroborates other reports from Thailand and suggests that enactment of PCV implementation could help reduce
antibiotic non-susceptibility, as was seen in the U.S. after vaccine introduction [30,31].

These findings document the ongoing burden of hospitalized pneumococcal bacteremia, which represents a small fraction of the total pneumococcal disease burden. In previous work among adults, we found that blood culture alone underestimates the burden. In previous work among pneumococcal researchers in Thailand, our findings highlight the potential impact of PCV in Thailand and underscore the need for cost-effectiveness data to inform vaccine policy discussions and decision making.

References


Acknowledgments

We would like to thank Guangkamoon Sudaipiyad, Anusak Kerdsin, Prasong Srisaengchai, and Sununta Henchaichon for their contributions to this project. We would also like to thank Maria da Gloria Carvalho and Matthew Moore from CDC, Atlanta, GA for their expert laboratory and epidemiology consultations.

Author Contributions

Conceived and designed the experiments: JR SD SAM PJ AK P. Salika. Performed the experiments: PJ AK P. Salika. Analyzed the data: JR PJ AK TA. Contributed reagents/materials/analysis tools: SD SAM AR P. Sawanpanyalert P. Akarasewi LFP. Wrote the paper: JR SAM LFP HCB. Maintained and cleaned database: TA.

PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e66038